As the therapeutic landscape for relapsed/refractory multiple myeloma (RRMM) continues to expand, the emergence of bispecific antibodies has introduced new challenges and opportunities in evaluating comparative clinical benefit. This session will provide a focused, methodologic, and clinically grounded exploration of Matching‑Adjusted Indirect Comparisons (MAICs)—a critical tool used to contextualize outcomes across studies in the absence of head‑to‑head trials.

Faculty will review the conceptual foundation of MAICs, including the key assumptions and statistics that underpin them and best‑practice methodological steps. Through case‑based examples featuring BCMA bispecifics, attendees will gain insight into how MAICs integrate patient‑level data to minimize cross‑trial heterogeneity and estimate comparative efficacy when randomized evidence is unavailable. Discussion will highlight strengths, limitations, and common pitfalls, emphasizing the appropriate interpretation of MAIC findings within the broader hierarchy of evidence.

The session will also examine how real‑world applications of MAICs inform regulatory and clinical decision‑making, including ways these analyses have been applied to investigational agents and how they complement data from registrational programs and observational studies. Attendees will leave equipped to critically evaluate MAIC outputs and incorporate these insights into evidence‑based therapeutic selection for patients with RRMM.

Copyright © 2026 Regeneron Pharmaceuticals, Inc.
All rights reserved. FR-LNVO-EM-26-01-0002 February 2026